Granatek C H, Ezaki K, Hersh E M, Keating M J, Rasmussen S
Cancer. 1981 Jan 15;47(2):272-9. doi: 10.1002/1097-0142(19810115)47:2<272::aid-cncr2820470211>3.0.co;2-c.
A solid-phase radioimmunoassay was utilized to evaluate the antibody response of 21 acute myelogenous leukemia (AML) patients to active specific immunotherapy with either pooled allogeneic AML blast cells or leukemia-associated antigen (LAA), admixed with BCG cell-wall skeleton (CWS). Five of 13 patients treated with LAA had a significant antibody response to LAA after immunotherapy. Antibody response correlated with an increased remission duration (159+ vs. 75+ weeks) and an increased survival (164+ vs. 98+ weeks). Two of eight patients treated with cells responded to LAA, and three patients had initially high anti-LAA antibody levels. In the total study, eight of 11 patients surviving longer than 2 1/2 years and six of seven patients maintaining a complete remission longer than 2 years were antibody responders. Neither protocol induced significant antibody to a normal spleen extract, BCG-CWS, or a measles recall antigen. However, five of seven patients with initially high levels of antibody to BCG (following weekly BCG scarification) were long-term survivors. These data suggest that the humoral immune response to immunotherapeutic agents may be a useful parameter for monitoring immunotherapy of AML patients.
采用固相放射免疫测定法评估21例急性髓性白血病（AML）患者对用混合异体AML原始细胞或白血病相关抗原（LAA）与卡介苗细胞壁骨架（CWS）混合进行的主动特异性免疫治疗的抗体反应。13例接受LAA治疗的患者中有5例在免疫治疗后对LAA有显著的抗体反应。抗体反应与缓解期延长（159 +对75 +周）和生存期延长（164 +对98 +周）相关。8例接受细胞治疗的患者中有2例对LAA有反应，3例患者最初抗LAA抗体水平较高。在整个研究中，11例存活超过2.5年的患者中有8例以及7例维持完全缓解超过2年的患者中有6例是抗体反应者。两种方案均未诱导出针对正常脾提取物、卡介苗 - CWS或麻疹回忆抗原的显著抗体。然而，7例最初对卡介苗抗体水平较高（每周进行卡介苗划痕接种后）的患者中有5例是长期存活者。这些数据表明，对免疫治疗药物的体液免疫反应可能是监测AML患者免疫治疗的一个有用参数。
